BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a cytoprotective protein identified in gastric juice.
In published in-vitro and animal-model research, BPC-157 has been studied for its effects on angiogenesis (the formation of new blood vessels), the migration of tendon and ligament fibroblasts, and the integrity of the gastrointestinal mucosa. Much of this work points to modulation of the nitric oxide (NO) system and of vascular endothelial growth factor (VEGF) signalling as proposed mechanisms.
It is important to note that the available evidence is preclinical. BPC-157 is not an approved medicine in the UK or elsewhere, and human clinical data are limited. It is studied as a research compound only.
For laboratory work, purity and identity matter: each Onyx Peptides vial is supplied as a lyophilised powder, independently HPLC-tested to at least 99% purity, with batch identity confirmed by mass spectrometry. Store the lyophilised vial below -18C until use.
This article is provided for educational and research-reference purposes only. It is not medical advice. All products are supplied strictly for in-vitro laboratory research use, not for human or veterinary consumption.